Donya Malekshahian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Donya Malekshahian has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Parissa Farnia
Mycobacteriology Research Centre (MRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD)
6 shared publications Shima Seif
Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 shared publications- Ali Akbar Velayati
Mycobacteriology Research Center, Director of the National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 shared publications - Mehdi Mirsaeidi
Division of Pulmonology & Critical Care, Department of Internal Medicine, Dell Medical School, The University of Texas, Austin, USA
2 shared publications Mohadese Mozafari
From the Mycobacteriology Research Centre, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publicationsSnaz Rahideh
From the Mycobacteriology Research Centre, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 18 September 2022
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 17 (3)
Mycobacterium simiae Isolates Subtypes and Molecular Drug Susceptibility in Iran
Background: Despite the clinical and epidemiological importance of Mycobacterium simiae worldwide, including in Iran, there is no clear and effective treatment regimen for M. simiae and its different subtypes. Objectives: Concerning the superiority of molecular approaches, this study aims to identify the common M. simiae subtypes submitted to the National Reference Tuberculosis (TB) Laboratory of Iran and study the presence of drug resistance by molecular detection methods. Methods: We included sputum samples with M. simiae confirmation submitted to the National Reference TB Laboratory of Iran from May 2014 to May 2016. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay was used for drug susceptibility testing (DST). Results: Among 7200 TB suspected patients, a total of 60 M. simiae cases belonging to subtype I were identified. All the included clinical isolates met the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) diagnostic criteria and were considered the disease’s causative pathogen. Males (58.33%), elderly (68.54%), and patients with a history of TB (51.42%) were shown to be more prone to infection with the disease. All clinical isolates of M. simiae were resistant to rifampin (RIF) and isoniazid (INH). Amikacin/kanamycin (AMK/KAN) and ciprofloxacin (CIP) susceptibility was found to be 91.66% and 88.33%, respectively. Conclusions: Subtype I was exclusively identified among M. simiae patients in Iran. Molecular detection of drug resistance suggests that amikacin/kanamycin and ciprofloxacin could be used to treat patients infected with M. simiae subtype I.
- 18 September 2022
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 17 (3)
Open AccessMycobacterium simiae Isolates Subtypes and Molecular Drug Susceptibility in Iran
Background: Despite the clinical and epidemiological importance of Mycobacterium simiae worldwide, including in Iran, there is no clear and effective treatment regimen for M. simiae and its different subtypes. Objectives: Concerning the superiority of molecular approaches, this study aims to identify the common M. simiae subtypes submitted to the National Reference Tuberculosis (TB) Laboratory of Iran and study the presence of drug resistance by molecular detection methods. Methods: We included sputum samples with M. simiae confirmation submitted to the National Reference TB Laboratory of Iran from May 2014 to May 2016. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay was used for drug susceptibility testing (DST). Results: Among 7200 TB suspected patients, a total of 60 M. simiae cases belonging to subtype I were identified. All the included clinical isolates met the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) diagnostic criteria and were considered the disease’s causative pathogen. Males (58.33%), elderly (68.54%), and patients with a history of TB (51.42%) were shown to be more prone to infection with the disease. All clinical isolates of M. simiae were resistant to rifampin (RIF) and isoniazid (INH). Amikacin/kanamycin (AMK/KAN) and ciprofloxacin (CIP) susceptibility was found to be 91.66% and 88.33%, respectively. Conclusions: Subtype I was exclusively identified among M. simiae patients in Iran. Molecular detection of drug resistance suggests that amikacin/kanamycin and ciprofloxacin could be used to treat patients infected with M. simiae subtype I.
- Open Access
- 1 December 2016
- Published by Medknow in International Journal of Mycobacteriology
- Vol. 5 (Suppl 1) , S215
Molecular drug susceptibility testing against the first-line (rifampin and isoniazid) and second-line (ciprofloxacin–amikacin and kanamycin) treatment in different subtypes of Mycobacterium simiae
Objective background: Mycobacterium simiae has been identified as the most prevalent slow growing mycobacteria that has been isolated among Iranian patients. Due to an importance of molecular approaches in the treatment of nontuberculosis mycobacteria, this study aimed to evaluate molecular drug susceptibility testing against the first-line (rifampin and isoniazid) and second-line (ciprofloxacin–amikacin and kanamycin) treatment in different subtypes of M. simiae . Methods: The study involved all patients presenting to our referral tuberculosis center from March 2014 to August 2016, with confirmation of M. simiae . For all sputum samples, after digestion and decontamination, followed by DNA extraction, polymerase chain reaction-restriction fragment length polymorphism was performed using the hsp65 gene. Furthermore, susceptibility to rifampin, isoniazid, ciprofloxacin, amikacin, and kanamycin were evaluated using rpoB , inhA , katG , gyrA , and rrs genes, respectively. Results: In total, 60 cases (58.33% men and 41.66% women) of M. simiae infections were identified and all were confirmed as subtype I. All the patients were resistant to the first line-tuberculosis drugs, while 88.33% and 91.66% of cases were susceptible to ciprofloxacin and both amikacin and kanamycin, respectively. Conclusion: Regarding the given result, first-line tuberculosis drugs should be excluded from the treatment regimen of M. simiae patients. In addition, subtype I seems to be the most or even the only isolated M. simiae subtype among all Iranian patients. While both amikacin and kanamycin drugs showed better efficacy in the treatment M. simiae , the most susceptible antibiotic is still indeterminate.
- 1 December 2016
- Published by Medknow in International Journal of Mycobacteriology
- Vol. 5 (Suppl 1) , S215
Open AccessMolecular drug susceptibility testing against the first-line (rifampin and isoniazid) and second-line (ciprofloxacin–amikacin and kanamycin) treatment in different subtypes of Mycobacterium simiae
Objective background: Mycobacterium simiae has been identified as the most prevalent slow growing mycobacteria that has been isolated among Iranian patients. Due to an importance of molecular approaches in the treatment of nontuberculosis mycobacteria, this study aimed to evaluate molecular drug susceptibility testing against the first-line (rifampin and isoniazid) and second-line (ciprofloxacin–amikacin and kanamycin) treatment in different subtypes of M. simiae . Methods: The study involved all patients presenting to our referral tuberculosis center from March 2014 to August 2016, with confirmation of M. simiae . For all sputum samples, after digestion and decontamination, followed by DNA extraction, polymerase chain reaction-restriction fragment length polymorphism was performed using the hsp65 gene. Furthermore, susceptibility to rifampin, isoniazid, ciprofloxacin, amikacin, and kanamycin were evaluated using rpoB , inhA , katG , gyrA , and rrs genes, respectively. Results: In total, 60 cases (58.33% men and 41.66% women) of M. simiae infections were identified and all were confirmed as subtype I. All the patients were resistant to the first line-tuberculosis drugs, while 88.33% and 91.66% of cases were susceptible to ciprofloxacin and both amikacin and kanamycin, respectively. Conclusion: Regarding the given result, first-line tuberculosis drugs should be excluded from the treatment regimen of M. simiae patients. In addition, subtype I seems to be the most or even the only isolated M. simiae subtype among all Iranian patients. While both amikacin and kanamycin drugs showed better efficacy in the treatment M. simiae , the most susceptible antibiotic is still indeterminate.
- Open Access
- 1 March 2015
- Published by Wolters Kluwer Health in International Journal of Mycobacteriology
- Vol. 4, 171
Prevalence of primary ethambutol resistance in new smear-positive pulmonary TB cases
IntroductionEthambutol (ETB) is an antimycobacterial agent that is most commonly used in combination with other drugs in the treatment of tuberculosis (TB). There is evidence that the drug exerts its bacteriostatic activity by inhibition of the enzyme that is a constituent of a mycobacterial cell wall. Studies have been shown that primary (pretreatment) resistance rates of Mycobacterium tuberculosis (MTB) to ethambutol vary widely, i.e., from 1% to as high as 14%. In the present study, the aim is to investigate the percent of primary resistance among new pulmonary TB cases.Material and methodsOne hundred sixty-five (n=165) newly positive TB patients were included in this study. The susceptibility and molecular typing were performed on all culture-positive isolates. Both nested allele-specific PCR and PCR-RLFP were used to identify ETB resistant isolates.ResultsOut of 165 newly diagnosed patients, 145 (88%) were sensitive to all drugs tested. In total, 20 drug-resistant isolates (13%) were detected by both methods. Four were MDR-TB (3%) and the remaining were mono-drug resistant (10%). Only 6 isolates showed resistance to ETB (4%).ConclusionThe results showed a lower rate of ETB mono-drug resistance in Iran, but more extensive studies are needed to get a clearer picture. Additionally, it was found out that the molecular methods are useful tools to rapidly identify resistant isolates
- 1 March 2015
- Published by Wolters Kluwer Health in International Journal of Mycobacteriology
- Vol. 4, 171
Open AccessPrevalence of primary ethambutol resistance in new smear-positive pulmonary TB cases
IntroductionEthambutol (ETB) is an antimycobacterial agent that is most commonly used in combination with other drugs in the treatment of tuberculosis (TB). There is evidence that the drug exerts its bacteriostatic activity by inhibition of the enzyme that is a constituent of a mycobacterial cell wall. Studies have been shown that primary (pretreatment) resistance rates of Mycobacterium tuberculosis (MTB) to ethambutol vary widely, i.e., from 1% to as high as 14%. In the present study, the aim is to investigate the percent of primary resistance among new pulmonary TB cases.Material and methodsOne hundred sixty-five (n=165) newly positive TB patients were included in this study. The susceptibility and molecular typing were performed on all culture-positive isolates. Both nested allele-specific PCR and PCR-RLFP were used to identify ETB resistant isolates.ResultsOut of 165 newly diagnosed patients, 145 (88%) were sensitive to all drugs tested. In total, 20 drug-resistant isolates (13%) were detected by both methods. Four were MDR-TB (3%) and the remaining were mono-drug resistant (10%). Only 6 isolates showed resistance to ETB (4%).ConclusionThe results showed a lower rate of ETB mono-drug resistance in Iran, but more extensive studies are needed to get a clearer picture. Additionally, it was found out that the molecular methods are useful tools to rapidly identify resistant isolates
- Open Access
- 1 March 2015
- Published by Wolters Kluwer Health in International Journal of Mycobacteriology
- Vol. 4, 107
Rapid identification of environmental NTM species using molecular genotyping
Background and objectiveNontuberculosis mycobacteria (NTM) are free-living saprophytes that are found in water, soil, animals and dairy products. During recent years, advances in molecular biology improved the recovery and accuracy of NTM identification. In the present study, similar approaches were used to differentiate environmental NTM. For this reason, the prevalence of environmental NTM in soil and water in two densely populated areas of Tehran were investigated.Material and methodsA total of 2,540 samples were collected from soil (n=1237) and water (n=1303) resources. For the soil sample: digestion and decontamination were performed using modified Engbaeks method, and for the water sample: decontamination followed with ethylpyridinium chloride (CPC; final concentration of 0.05%) and standard protocol. The phenotypic and genotyping tests were performed on all positive cultures. For molecular tests, both 16S-23S RNA and hsp65 genes spacer PCR-RFLP were used.ResultsOf the 2,540 collected samples, 285 (12%) were positive for mycobacterium. One hundred and sixty-nine (169; 60%) belonged to a slow growing mycobacteria (SGM) and 116 (41%) were rapid growing mycobacteria (RGM). The most frequent NTM were identified as Mycobacterium farcinogenes (51/485; 10.5%) and Mycobacterium fortuitum (38/485; 7.8%). However, M. farcinogenes is found to be dominant in both studied areas, but the frequency of RGM was different. In Shahre-ray, Mycobacterium senegalense was identified as the most frequent RGM (22/65; 34%), while in Varamin, M. fortuitum (20/51; 40%) had the most frequency.ConclusionThe molecular genotyping methods facilitate the rapid identification of environmental NTM. As the higher prevalence of NTM within a region increases the risk of human infection, this study outlines the importance of further investigation
- 1 March 2015
- Published by Wolters Kluwer Health in International Journal of Mycobacteriology
- Vol. 4, 107
Open AccessRapid identification of environmental NTM species using molecular genotyping
Background and objectiveNontuberculosis mycobacteria (NTM) are free-living saprophytes that are found in water, soil, animals and dairy products. During recent years, advances in molecular biology improved the recovery and accuracy of NTM identification. In the present study, similar approaches were used to differentiate environmental NTM. For this reason, the prevalence of environmental NTM in soil and water in two densely populated areas of Tehran were investigated.Material and methodsA total of 2,540 samples were collected from soil (n=1237) and water (n=1303) resources. For the soil sample: digestion and decontamination were performed using modified Engbaeks method, and for the water sample: decontamination followed with ethylpyridinium chloride (CPC; final concentration of 0.05%) and standard protocol. The phenotypic and genotyping tests were performed on all positive cultures. For molecular tests, both 16S-23S RNA and hsp65 genes spacer PCR-RFLP were used.ResultsOf the 2,540 collected samples, 285 (12%) were positive for mycobacterium. One hundred and sixty-nine (169; 60%) belonged to a slow growing mycobacteria (SGM) and 116 (41%) were rapid growing mycobacteria (RGM). The most frequent NTM were identified as Mycobacterium farcinogenes (51/485; 10.5%) and Mycobacterium fortuitum (38/485; 7.8%). However, M. farcinogenes is found to be dominant in both studied areas, but the frequency of RGM was different. In Shahre-ray, Mycobacterium senegalense was identified as the most frequent RGM (22/65; 34%), while in Varamin, M. fortuitum (20/51; 40%) had the most frequency.ConclusionThe molecular genotyping methods facilitate the rapid identification of environmental NTM. As the higher prevalence of NTM within a region increases the risk of human infection, this study outlines the importance of further investigation
- Open Access
- 1 March 2015
- Published by Wolters Kluwer Health in International Journal of Mycobacteriology
- Vol. 4, 106
Laboratory quality stepwise implementation tool: National reference TB laboratory of Iran
Background and objectiveDuring recent years, the World Health Organization (WHO) proposed new software for improving the tuberculosis (TB) laboratory services. The protocol is known as “quality stepwise implementation tool” and is based on enforcement of quality assurance services through accreditation by the International Organization for Standardization (ISO) 15189. As a national reference TB laboratory (NRL) of Iran, the benefit and challenges of implementing this standard were analyzed.Material and methodsThe investigation was a cross-sectional study and was underlined by the committee of the Quality Management System (QMS) in the NRL. The required information was collected in two steps: first, the QC form that contains 334 quality questions (designed by WHO) was filled out. These questions determine 12 main organizational blocks of laboratory (facilities and safety1¸ organization and personnel2¸ documents and records3¸ management reviews4¸ client management and customer service5¸ equipment6¸ internal audit7¸ purchasing and inventory8¸ information management9¸ process control and internal / external quality management10¸ corrective actions occurrence11, and incident management and process improvement12). The minimum rating of laboratories is stated to be from 55% to a maximum of 95%. In the second step, using the quality stepwise implementation tool, these blocks were in four phases, and 41 steps were analyzed. The data were compared using Fisher’s Exact test and Pearson Chi-Square.ResultsIn the period 2013–2014, the rate of OMS in three focal points (pre-analytical¸ analytical¸ and post-analytical) in the NRL was in the range of 80–100%; whereas in previous years the rate ranged from 48% to 79%. Therefore, through QMS the NRL scores had reached a higher level. Based on available results, the NRL-assigned score was a 5-star rating.ConclusionsAs the internal score of NRL reaches 5, an international evaluation of accreditation scheme is sought. This is the first investigation that used the quality stepwise implementation tool in Iran
- 1 March 2015
- Published by Wolters Kluwer Health in International Journal of Mycobacteriology
- Vol. 4, 106
Open AccessLaboratory quality stepwise implementation tool: National reference TB laboratory of Iran
Background and objectiveDuring recent years, the World Health Organization (WHO) proposed new software for improving the tuberculosis (TB) laboratory services. The protocol is known as “quality stepwise implementation tool” and is based on enforcement of quality assurance services through accreditation by the International Organization for Standardization (ISO) 15189. As a national reference TB laboratory (NRL) of Iran, the benefit and challenges of implementing this standard were analyzed.Material and methodsThe investigation was a cross-sectional study and was underlined by the committee of the Quality Management System (QMS) in the NRL. The required information was collected in two steps: first, the QC form that contains 334 quality questions (designed by WHO) was filled out. These questions determine 12 main organizational blocks of laboratory (facilities and safety1¸ organization and personnel2¸ documents and records3¸ management reviews4¸ client management and customer service5¸ equipment6¸ internal audit7¸ purchasing and inventory8¸ information management9¸ process control and internal / external quality management10¸ corrective actions occurrence11, and incident management and process improvement12). The minimum rating of laboratories is stated to be from 55% to a maximum of 95%. In the second step, using the quality stepwise implementation tool, these blocks were in four phases, and 41 steps were analyzed. The data were compared using Fisher’s Exact test and Pearson Chi-Square.ResultsIn the period 2013–2014, the rate of OMS in three focal points (pre-analytical¸ analytical¸ and post-analytical) in the NRL was in the range of 80–100%; whereas in previous years the rate ranged from 48% to 79%. Therefore, through QMS the NRL scores had reached a higher level. Based on available results, the NRL-assigned score was a 5-star rating.ConclusionsAs the internal score of NRL reaches 5, an international evaluation of accreditation scheme is sought. This is the first investigation that used the quality stepwise implementation tool in Iran
- Open Access
- 8 December 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (12) , e114428
Molecular Epidemiology of Nontuberculous Mycobacteria Isolates from Clinical and Environmental Sources of a Metropolitan City
While NTM infection is mainly acquired from environmental exposure, monitoring of environmental niches for NTM is not a routine practice. This study aimed to find the prevalence of environmental NTM in soil and water in four highly populated suburbs of Tehran, Iran. A total of 4014 samples from soil and water resources were collected and studied. Sediments of each treated sample were cultured in Lowenstein-Jensen medium and observed twice per week for growth rate, colony morphology, and pigmentation. Colonies were studied with phenotypic tests. Molecular analysis was performed on single colonies derived from subculture of original isolates. Environmental samples were compared with 34 NTM isolates from patients who were residents of the study locations. Out of 4014 samples, mycobacteria were isolated from 862 (21.4%) specimens; 536 (62.1%) belonged to slow growing mycobacteria (SGM) and 326 (37.8%) were rapid growing mycobacteria (RGM). The five most frequent NTM were M. farcinogens (105/862; 12.1%), M. fortuitum (72/862; 8.3%), M. senegalense (58/862; 6.7%), M. kansasii (54/862; 6.2%), and M. simiae (46/862; 5.3%). In total, 62.5% (539/862) of mycobacterial positive samples were isolated from water and only 37.4% (323/862) of them were isolated from soil samples (PM. simiae (51; 29.1%), M. kansasii (26; 14.8%), M. chelonae (28; 16%), and M. fortuitum (13; 7.4%). Comparing the distribution pattern of environmental NTM isolates with clinical isolates suggests a possible transmission link, but this does not apply to all environmental NTM species. Our study confirms an increasing trend of NTM isolation from clinical samples that needs further investigation.
- 8 December 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (12) , e114428
Open AccessMolecular Epidemiology of Nontuberculous Mycobacteria Isolates from Clinical and Environmental Sources of a Metropolitan City
While NTM infection is mainly acquired from environmental exposure, monitoring of environmental niches for NTM is not a routine practice. This study aimed to find the prevalence of environmental NTM in soil and water in four highly populated suburbs of Tehran, Iran. A total of 4014 samples from soil and water resources were collected and studied. Sediments of each treated sample were cultured in Lowenstein-Jensen medium and observed twice per week for growth rate, colony morphology, and pigmentation. Colonies were studied with phenotypic tests. Molecular analysis was performed on single colonies derived from subculture of original isolates. Environmental samples were compared with 34 NTM isolates from patients who were residents of the study locations. Out of 4014 samples, mycobacteria were isolated from 862 (21.4%) specimens; 536 (62.1%) belonged to slow growing mycobacteria (SGM) and 326 (37.8%) were rapid growing mycobacteria (RGM). The five most frequent NTM were M. farcinogens (105/862; 12.1%), M. fortuitum (72/862; 8.3%), M. senegalense (58/862; 6.7%), M. kansasii (54/862; 6.2%), and M. simiae (46/862; 5.3%). In total, 62.5% (539/862) of mycobacterial positive samples were isolated from water and only 37.4% (323/862) of them were isolated from soil samples (PM. simiae (51; 29.1%), M. kansasii (26; 14.8%), M. chelonae (28; 16%), and M. fortuitum (13; 7.4%). Comparing the distribution pattern of environmental NTM isolates with clinical isolates suggests a possible transmission link, but this does not apply to all environmental NTM species. Our study confirms an increasing trend of NTM isolation from clinical samples that needs further investigation.